Affymetrix, Inc. (NASDAQ: AFFX) will be highlighting several new genotyping arrays at the 2015 Plant and Animal Genome Conference (PAGXXIII) for applications in breeding and routine analysis. Affymetrix now offers the largest catalog of arrays for research and applied agriculture markets. The newest arrays, Axiom ® Porcine Genotyping Array and Axiom Equine Genotyping Array, each with more than 600,000 markers, will be available to the agriculture community under the Axiom Expert Design Program. These two high-density arrays add to the product portfolio that includes bovine, chicken, maize, salmon, and wheat. Affymetrix has recently launched arrays with the newest content for genomic breeding in soybean and cotton, and arrays for buffalo, rainbow trout, rose, and strawberry. Also new are enhanced wheat arrays that have come out of the UK-based Wheat Institute Strategic Programme (WISP), which began using Axiom arrays early last year. "Axiom genotyping technology offers the agriculture community the capabilities to rapidly design and develop custom arrays," said Dr. Laurent Bellon, Senior Vice President and General Manager of Genetic Analysis Business Unit at Affymetrix. "Array-based genotyping empowers the agriculture community around the world with powerful yet easy-to-use genomic tools to rapidly address the challenges posed by the growing food requirements of our world." The arrays will be featured at the Affymetrix workshop that will include three talks from industry experts on Monday, January 12 at PAG XXIII. The talks will cover the latest genomic techniques for research and breeding in pigs, strawberry, and Medicago truncatula. Affymetrix is at the forefront of plant and animal genotyping and gene expression analysis with Axiom genotyping arrays and GeneChip ® gene expression arrays for more than 50 plant and animal species. With Affymetrix' advanced bioinformatics and innovative design strategies, Axiom arrays routinely support genome-wide genotyping and accurately call the genotypes of both diploid and polyploid species.
The catalog of Axiom agrigenomics genotyping arrays, gene expression arrays, reagents, and powerful bioinformatics software that can address diploid and polyploid genomes gives scientists the toolbox to advance their research and commercial objectives by translating discoveries to routine applications.To learn more about the Axiom Genotyping Solution for applications in agrigenomics, please visit www.affymetrix.com/agrigenomics. PLEASE NOTE: The Affymetrix logo, Affymetrix, Axiom, and GeneChip are registered trademarks of Affymetrix, Inc. All other trademarks and names are the property of their respective owners. About Affymetrix Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. The Company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,500 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com. Forward-looking statements All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2013, and other SEC reports for subsequent quarterly periods.